How Common Infections Cause One in Eight Cancers Worldwide

2026-10-14 global

Geneva, Wednesday, 14 October 2026.
A global study reveals that treatable and preventable infections caused 12 percent of new global cancer cases in 2024, highlighting a major opportunity for preventative healthcare.

Global Cancer Burden Linked to Preventable Infections

A groundbreaking study published on October 13, 2026, reveals that infectious agents were responsible for approximately 12 percent of all new cancer diagnoses worldwide in 2024 [1][2]. Conducted by the World Health Organization’s International Agency for Research on Cancer (IARC), the research estimates that 2.3 million cancer cases globally in 2024 were attributable to infections, representing one in eight total cancer cases [3][6]. This data underscores a critical intersection between infectious disease control and oncology, suggesting that a significant portion of the global cancer burden is preventable through existing medical interventions [7]. The findings were released this week, highlighting the urgency for policymakers to integrate infection control into long-term cancer reduction strategies [5].

Primary Pathogens and Biological Mechanisms

The analysis identifies five primary pathogens responsible for the majority of infection-linked cancers, with Helicobacter pylori and human papillomavirus (HPV) each accounting for 4 percent of all new cancer diagnoses in 2024 [3][5]. Hepatitis B virus contributed to 2 percent of cases, while the Epstein-Barr virus (EBV) and Hepatitis C virus accounted for 1 percent and less than 1 percent respectively [5][7]. These pathogens induce oncogenesis through mechanisms such as inactivating cell division-stopping proteins like TP53, inserting viral DNA into host DNA, or triggering chronic inflammation that damages DNA during cell replication [3][5]. H. pylori transmission occurs via saliva or contaminated food and water, while Hepatitis B and HPV are preventable via vaccination, and Hepatitis C is curable with short-course antivirals [7][8].

Vaccine Efficacy and Prevention Gaps

Preventative tools exist for many of these infections, yet coverage gaps remain a critical barrier to reducing cancer incidence. The HPV vaccine, approved 20 years ago in 2006, is designed to prevent cervical cancer, and epidemiologists expect to see measurable impacts on cancer rates as vaccinated cohorts age [2]. The hepatitis B virus vaccine was the first vaccine developed specifically against cancer, yet access remains uneven globally [2]. In Australia, where the HPV vaccination program initiated in 2007 reduced infections by 90 percent among eligible populations, vaccination coverage for 15-year-olds declined from 85.7 percent in 2020 to 79.5 percent in 2024 [3][5]. This decline represents a percentage drop of -7.235 in coverage over four years, posing a risk to elimination targets [3]. Furthermore, while tools exist to protect against Hepatitis B and HPV, no effective vaccine currently exists for the Epstein-Barr virus, a nearly ubiquitous pathogen linked to cancer [2][5].

Global Equity and Economic Implications

The study highlights a significant global health equity gap, with approximately 75 percent of cancers caused by infectious agents occurring in low- and middle-income countries [3][5]. This disparity emphasizes the financial and social benefits of shifting resources toward preventative healthcare strategies to reduce the long-term economic burden of oncology care [1]. Australia aims to eliminate cervical cancer by 2035, and the WHO has set a target to reach 90 percent HPV vaccination coverage for 15-year-old girls by 2030 [3][5]. Experts note that historically siloing infectious diseases and oncology has hindered progress, but aggressive infection control could vaccinate and treat millions out of future cancer diagnoses [7]. The publication of this study serves as a current effort to prioritize infection control and prevention strategies as a means to reduce global cancer incidence [5].

Sources

Oncology Preventive Healthcare